If you visit a fast-food chain in the next few years, expect the menu to look a little less gluttonous.

In between the usual deep-fried options, industry observers anticipate more offerings that come in smaller portions, pack nutrients like protein or fibre and check enough boxes to be considered healthy.

The changes aren’t just a reflection of our growing predilection for snacking or our ongoing quest to trim down our tabs — and waists. They’re also because more people have shrinking appetites triggered by injectable drugs like Ozempic, Wegovy and Mounjaro.

These glucagon-like peptide-1 receptor agonists, or GLP-1s, were predominantly used to treat diabetes until the masses realized they slow down emptying of the stomach, causing people to feel full longer than without the drug. Ipsos

See Full Page